BioSyent Annonce L'Introduction du Nouveau FeraMAX® Pd
05 oct. 2020 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, 05 oct. 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », « la Société », Bourse de croissance : RX) a le plaisir d’annoncer l’introduction de FeraMAX® Pd, une nouvelle...
BioSyent Announces Introduction of New FeraMAX® Pd
05 oct. 2020 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 05, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the introduction of FeraMAX® Pd, a new oral iron supplement...
FibroGen to Report Second Quarter 2020 Financial Results
23 juil. 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will...
FibroGen to Present at Upcoming Investor Conferences
27 mai 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
08 mai 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May...
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
02 mars 2020 16h01 HE
|
FibroGen, Inc
Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic...
FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease
23 déc. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
02 déc. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s...
American Kidney Fund Highlights Critical Public Health Education Programs at ASN Kidney Week, Booth #2717
07 nov. 2019 09h00 HE
|
American Kidney Fund
WASHINGTON, D.C., Nov. 07, 2019 (GLOBE NEWSWIRE) -- At the American Society of Nephrology (ASN) Kidney Week 2019 Annual Meeting in Washington, D.C., the American Kidney Fund (AKF) is launching its...
FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019
04 nov. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November...